抑制hIAP-2在MCF7乳腺癌细胞中的表达增强抗肿瘤药物的抑癌作用

目的 探讨抑制hIAP-2在MCF7乳腺癌细胞中的表达增强对肿瘤化疗药物抑癌作用的影响。方法 采用MTT法检测mU6/hIAP-2质粒与多种常规肿瘤化疗药物对乳腺癌MCF-7细胞增殖的联合作用。结果 比较单纯化疗药物作用组的各相应浓度点，siRNA表达质粒mU6/hIAP-2与化疗药物顺铂、环磷酰胺或5-氟尿嘧啶合用组对乳腺癌细胞MCF-7的细胞增殖抑制率均明显提高，差异有显著性（p<0.01），但与秋水仙碱合用组对乳腺癌细胞MCF-7的细胞增殖抑制率明显降低，差异有显著性（p<0.01）；对靶向DNA药物如顺铂、环磷酰胺和5-氟尿嘧啶的抗癌性能具有显著的协同增强作用（二者合用效应Q值均≥1），但对靶向微管的药物秋水仙碱具有拮抗作用（Q值<1）。结论 在敲除乳腺癌细胞中人凋亡抑制蛋白-2功能的基础上进行药物化疗，可能是乳腺癌治疗的一个新的可行方向。

Inhibiting hIAP-2 expression in MCF-7 cells enhances anti-tumor roles of chemotherapeutic drugs

【Abstract】 Objective We have already reported that siRNA expression plasmid mU6/hIAP-2 which we constructed can knockdown hIAP-2 and inhibit the proliferation of MCF-7 cells dramatically and specifically. And now, we focus on exploring its influence on anti-tumor function of chemotherapeutic drugs. Methods MTT method is used to determine its combination effect on cell proliferation of MCF-7 with several chemotherapeutic drugs. Results Compared with the groups only with drug in different responsive concentration, its inhibitory rate on MCF-7 cell proliferation has been increased significantly in the groups which combined plasmid mU6/hIAP-2 with cysplatin, cyclophosphamide, or 5-fluorouracil (p<0.01, respectively), but decreased significantly in groups which combined plasmid mU6/hIAP-2 with colchincine (p<0.01, respectively); plasmid mU6/hIAP-2 cooperative enhances the anti-tumor ability of some drugs target DNA like as cysplatin, cyclophosphamide and 5-fluorouracil (all combination effect Q value>1), but have no plus effect on colchincine target microtubule (Q value<1). Conclusion It might be a new therapy direction to treat breast tumor with chemotherapeutic drugs under the background deprived hIAP-2 functions.